Difference between revisions of "Team:Evry"
| Line 20: | Line 20: | ||
<p class="text-justify"> | <p class="text-justify"> | ||
| − | Cancer thrives by preventing the <strong>immune system</strong> from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To develop <strong>personalized therapies</strong>, our team focused on engineering yeast <em>Saccharomyces cerevisiae</em> for targeted immunotherapy. First, we developed a <strong>software to select the best tumor antigen</strong> from patient sequencing data. Second, we created a <strong>yeast chassis</strong> to prime the immune system with the targeted antigen. This chassis was tested <em>in vitro</em> on mouse splenocytes and <em>in vivo</em> on mice presenting melanoma with significant results. Three complementary strategies were combined to induce the immune system. First, in order to modulate the <strong>tumor environment</strong>, yeast secreting the specific immune modulator IFNgamma was encapsulated into alginate beads to be injected in tumors. Secondly, to <strong>break the immune tolerance</strong> against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system that can be adapted to any tumor antigen for personalized therapy. Last, to <strong>deliver cytotoxic compounds</strong> solely in the tumor environment, a yeast hypoxia bio-sensor was designed | + | Cancer thrives by preventing the <strong>immune system</strong> from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To develop <strong>personalized therapies</strong>, our team focused on engineering yeast <em>Saccharomyces cerevisiae</em> for targeted immunotherapy. First, we developed a <strong>software to select the best tumor antigen</strong> from patient sequencing data. Second, we created a <strong>yeast chassis</strong> to prime the immune system with the targeted antigen. This chassis was tested <em>in vitro</em> on mouse splenocytes and <em>in vivo</em> on mice presenting melanoma with significant results. Three complementary strategies were combined to induce the immune system. First, in order to modulate the <strong>tumor environment</strong>, yeast secreting the specific immune modulator IFNgamma was encapsulated into alginate beads to be injected in tumors. Secondly, to <strong>break the immune tolerance</strong> against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system that can be adapted to any tumor antigen for personalized therapy. Last, to <strong>deliver cytotoxic compounds</strong> solely in the tumor environment, a yeast hypoxia bio-sensor was designed. Our <strong>standardized</strong> and <strong>customizable</strong> chassis takes advantage of these approaches to make personalized medicine a reality, with a scalable cancer therapy.</p> |
</section> | </section> | ||
Revision as of 21:19, 18 September 2015
Let's begin with a small abstract
Cancer thrives by preventing the immune system from targeting tumor cells. While current immunotherapies use dendritic cells to activate T-cells towards specific tumor antigens, they remain expensive and of variable efficiency against tumor immunosuppressive environment. To develop personalized therapies, our team focused on engineering yeast Saccharomyces cerevisiae for targeted immunotherapy. First, we developed a software to select the best tumor antigen from patient sequencing data. Second, we created a yeast chassis to prime the immune system with the targeted antigen. This chassis was tested in vitro on mouse splenocytes and in vivo on mice presenting melanoma with significant results. Three complementary strategies were combined to induce the immune system. First, in order to modulate the tumor environment, yeast secreting the specific immune modulator IFNgamma was encapsulated into alginate beads to be injected in tumors. Secondly, to break the immune tolerance against cancer cells, T4 and T8 lymphocytes were elicited by a yeast antigen display system that can be adapted to any tumor antigen for personalized therapy. Last, to deliver cytotoxic compounds solely in the tumor environment, a yeast hypoxia bio-sensor was designed. Our standardized and customizable chassis takes advantage of these approaches to make personalized medicine a reality, with a scalable cancer therapy.
To top